|
| << vorige | volgende >> |
Tijdschrift beschrijving
Alle jaargangen van het bijbehorende tijdschrift
Alle afleveringen van het bijbehorende jaargang
Alle artikelen van de bijbehorende aflevering
Details van artikel 6 van 21 gevonden artikelen
| Titel: |
Clinical applications of phage-derived sFvs and sFv fusion proteins |
| Auteur: |
K.A. Chester J. Bhatia G. Boxer S.P. Cooke A.A. Flynn A. Huhalov A. Mayer R.B. Pedley L. Robson S.K. Sharma D.I.R. Spencer R.H.J. Begent |
| Verschenen in: |
Disease markers |
| Paginering: | Jaargang 16 (2001) nr. 1-2 pagina's 53-62 |
| Jaar: |
2001-04-01 |
| Inhoud: |
Single chain Fv antibodies (sFvs) have been produced from filamentous bacteriophage libraries obtained from immunised mice. MFE-23, the most characterised of these sFvs, is reactive with carcinoembryonic antigen (CEA), a glycoprotein that is highly expressed in colorectal adenocarcinomas. MFE-23 has been expressed in bacteria and purified in our laboratory for two clinical trials; a gamma camera imaging trial using ^{123}I-MFE-23 and a radioimmunoguided surgery trial using^{125}I-MFE-23, where tumour deposits are detected by a hand-held probe during surgery. Both these trials show MFE-23 is safe and effective in localising tumour deposits in patients with cancer. We are now developing fusion proteins which use MFE-23 to deliver a therapeutic moiety; MFE-23::CPG2 targets the enzyme carboxypeptidase G2 (CPG2) for use in the ADEPT (antibody directed enzyme prodrug therapy) system and MFE::TNF\alpha aims to reduce sequestration and increase tumor concentrations of systemically administered TNF\alpha. |
| Uitgever: |
IOS Press |
| Bronbestand: |
Elektronische Wetenschappelijke Tijdschriften |
Details van artikel 6 van 21 gevonden artikelen
| << vorige | volgende >> |